Following the news, which was announced on 19 September, ARS’s stock dropped by over 50% in pre-market trading. Image Credit: Alexandr Shatilov / Shutterstock.

The US Food and Drug Administration (FDA) has asked for repeat-dose study results before granting approval for ARS Pharmaceuticals’s neffy (epinephrine nasal spray).

ARS plans to file a formal dispute resolution request (FDRR) to appeal the demand, which was made as part of the complete response letter (CRL) regarding its new drug application (NDA) for neffy.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Following the news, which was announced late on 19 September, ARS’s stock dropped by more than 50% in today’s pre-market trading.

Neffy is being investigated for the treatment of Type 1 allergic reactions, including anaphylaxis in adults and children who weigh ≥30 kg. Type 1 allergic reactions require immediate treatment following exposure to an allergen such as food, venom or insect stings.

Back and forth with the FDA

The requested pharmacokinetic/pharmacodynamic study would compare repeat doses of neffy to an epinephrine injection in allergen-induced allergic rhinitis conditions. This request to complete the study before approval is a reversal of a previous discussion by the FDA and ARS to conduct a repeat-dose study as part of a post-marketing plan.

See Also:

In May, the FDA Pulmonary-Allergy Advisory Committee (PADAC) recommended neffy’s approval without any additional trial data. The committee voted 16:6 in favour of using neffy in adults, and 17:5 in favour of its usage in children.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

ARS’s CEO Richard Lowenthal expressed his dismay, stating: “[Multiple] committee members highlighted the favourable profile of neffy in our completed single-dose nasal allergy challenge study and that any decline in exposure 20 minutes after dosing, after the expected response period, is of no concern.”

The US-based company plans to refile the NDA in H1 2024 and expects an action date to be set for H2 2024.

Neffy is currently under review for approval by the European Medicines Agency (EMA), with an option from the Committee for Medicinal Products for Human Use (CHMP) expected by the end of 2023. ARS also plans to file for regulatory approval in other countries in 2024.

The CRL issued by the FDA also requested information on nitrosamine impurities, which are potentially carcinogenic. However, ARS does not believe that the additional testing to generate the information would have any impact on the timeline for the new NDA.